After subcutaneous inoculation of Ehrlich carcinoma cells, complete regression of tumors was observed in 507 of 1429 dd/Y mice which were given intradermal injections of a lipopolysaccharide from
Proteus vulgaris. Sera from resistant mice obtained four weeks after challenges with tumor cells showed neutralizing activity
in vivo against Ehrlich carcinoma cells, and sarcoma-180 and MM2 cells, but not against SR-DDD or MH-134 tumor cells. These sera showing neutralizing activity
in vivo did not show either complement-dependent cytotoxicity or agglutinating activity against Ehrlich carcinoma cells
in vitro. The neutralizing activity was not inhibited by anti-mouse immunoglobulin-G and -M sera. In resistant mice, the growth of tumor cells in diffusion chambers was partially inhibited without cell-mediated responses, but transplantability of the cells in the chambers was unaffected. Incubation of Ehrlich carcinoma cells with these sera from resistant mice to allow absorption did not alter their neutralization titers. These results demonstrate that a humoral factor other than a conventional antibody is involved in the regression of Ehrlich carcinoma in these mice, and that one of the antitumor actions of this lipopolysaccharide is to increase production of this factor.
View full abstract